empagliflozin; metformin hydrochloride - Profile

What are the generic sources for empagliflozin; metformin hydrochloride and what is the scope of freedom to operate?

Empagliflozin; metformin hydrochloride is the generic ingredient in three branded drugs marketed by Boehringer Ingelheim and Zydus Pharms, and is included in three NDAs. There are sixteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Empagliflozin; metformin hydrochloride has four hundred and fifty-two patent family members in forty-seven countries.

Summary for empagliflozin; metformin hydrochloride

International Patents:	452
US Patents:	16
Tradenames:	3
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for empagliflozin; metformin hydrochloride

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for empagliflozin; metformin hydrochloride

Dosage:

TABLET, EXTENDED RELEASE;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYNJARDY	Tablets	empagliflozin; metformin hydrochloride	5 mg/500 mg 5 mg/1000 mg 12.5 mg/500 mg 12.5 mg/1000 mg	206111	4	2018-08-01
SYNJARDY XR	Extended-release Tablets	empagliflozin; metformin hydrochloride	5 mg/1000 mg 10 mg/1000 mg 12.5 mg/1000 mg 25 mg/1000 mg	208658	3	2018-08-01

US Patents and Regulatory Information for empagliflozin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No					Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016		RX	Yes	No					Y

Expired US Patents for empagliflozin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-003	Dec 9, 2016
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-001	Dec 9, 2016
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-002	Dec 9, 2016
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016

International Patents for empagliflozin; metformin hydrochloride

Country	Patent Number	Title	Estimated Expiration
Australia	2014247092
Canada	2812519
Canada	2908635
Canada	3121761
Chile	2015002940

Supplementary Protection Certificates for empagliflozin; metformin hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1730131	C300696	Netherlands		PRODUCT NAME: EMPAGLIFLOZINE EN ZOUTEN DAARVAN, IN HET BIJZONDER EMPAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/14/930/001-009 20140522
1730131	122014000099	Germany		PRODUCT NAME: EMPAGLIFLOZIN UND DESSEN SALZE, INSBESONDERE EMPAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/14/930 20140522
1730131	CR 2014 00054	Denmark		PRODUCT NAME: EMPAGLIFLOZIN OG SALTE DERAF, SAERLIGT EMPAGLIFLOZIN; REG. NO/DATE: EU1/14/930/001/018 20140527
1730131	C20140033 00134	Estonia		PRODUCT NAME: EMPAGLIFLOSIIN;REG NO/DATE: EU/1/14/930 27.05.2014
1730131	C01730131/04	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 63227 13.09.2021

Empagliflozin and Metformin Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

This analysis examines the investment landscape, market dynamics, and financial prospects for the combined use of empagliflozin—a sodium-glucose co-transporter 2 (SGLT2) inhibitor—and metformin hydrochloride, a cornerstone in type 2 diabetes mellitus (T2DM) treatment. The global diabetes therapeutics market is experiencing rapid growth driven by escalating diabetes prevalence, advances in drug development, and shifting regulatory landscapes. Key players include established pharmaceutical companies and innovative biotech firms, with a focus on cardio-renal protective agents like empagliflozin. This document provides a comprehensive overview of market size, drivers, competitive landscape, regulatory factors, financial forecasts, and strategic insights tailored for stakeholders evaluating investment opportunities in this therapeutic class.

---

What is the Market Size and Growth Potential for Empagliflozin combined with Metformin?

Parameter	Details
Global Diabetes Drugs Market (2022)	$93.6 billion (Fortune Business Insights) [1]
Projected CAGR (2022–2028)	~7.0% (Grand View Research)
Primary Treatment Regimen	Metformin + SGLT2 inhibitors (empagliflozin among top choices)
Empagliflozin Market Share (2022)	Estimated 10-12% of SGLT2 class revenue [2]
Global Prescriptions (2022)	~250 million T2DM patients worldwide; drug adherence improving, expanding markets
Key Growth Drivers	Rising T2DM prevalence, cardiovascular and renal benefits, patent expirations of competitors
Potential Revenue (2028)	$12–15 billion for empagliflozin + metformin combos (projection based on market expansion)**

---

What Are the Market Dynamics Influencing Empagliflozin and Metformin?

1. Epidemiological Drivers

• Prevalence of Type 2 Diabetes Mellitus: Approx. 537 million adults globally (IDF, 2021), projected to reach 700 million by 2045.
• Complication Burden: Cardiovascular disease, chronic kidney disease (CKD), and heart failure increase demand for agents with cardio-renal benefits.

2. Clinical Evidence and Guidelines

• Empagliflozin's Cardio-Renal Benefits: Demonstrated in EMPA-REG OUTCOME trial (2015), reducing cardiovascular mortality by 38% [3].
• Guideline Endorsements: American Diabetes Association (ADA) recommends SGLT2 inhibitors for patients with high cardiovascular or renal risk alongside metformin.

3. Regulatory Landscape

• Approvals: Empagliflozin approved in over 80 countries for T2DM, heart failure, and CKD.
• Patents & Exclusivity: Empagliflozin patent expiry dates vary; initial patents in the US expired in 2022, with exclusivity extensions via formulation patents.

4. Competitive Dynamics

Key Companies	Market Share	Product Portfolio	Strategic Moves
Boehringer Ingelheim & Eli Lilly	Leading (empagliflozin)	Jardiance (brand name for empagliflozin)	Expansion into combination therapies, biosimilars
Novo Nordisk	N/A	Oral and injectable antidiabetics	Focus on insulin, GLP-1 receptor agonists
Others (e.g., AstraZeneca)	Niche	SGLT2 inhibitors (e.g., dapagliflozin)	Diversification, pipeline development

5. Pricing & Reimbursement Dynamics

• Price Points: Empagliflozin generates ~$350–$500/month per patient.
• Insurance & Reimbursement: High in developed markets, variable in emerging markets.

6. R&D and Pipeline Outlook

• Emerging Combinations: Fixed-dose combinations (FDCs) with metformin to improve adherence.
• Pipeline Developments: Novel SGLT2 inhibitors with enhanced selectivity, renal protective properties.

---

What Are the Financial Trajectories and Investment Risks?

Revenue and Profitability Projections

Year	Estimated Global Sales ($ billion)	Growth Rate	Key Assumptions
2022	3.2 (empagliflozin alone)	—	Based on current market share and prescription data
2023–2025	4.5 – 6.7	8–15% CAGR	Increased adoption, penetration in emerging markets
2026–2028	8.0 – 12.0	10–12% CAGR	Expanded label indications, widening use in CKD, HF

Notes:

• Revenue projections account for patent expirations, generics entry, and potential label expansions.
• Margins are expected to improve through biosimilars and cost efficiencies.

Investment Risks

Risk Factor	Impact	Mitigation Strategies
Patent expirations	Revenue erosion post-2022 for some markets	Diversify portfolios, pipeline diversification
Regulatory changes	Stringent approval process, pricing controls	Engagement with regulators early, adaptive strategies
Competition from generics	Price erosion, decreased market share	Investment in innovation, branding, and loyalty
Clinical efficacy and safety	Negative trial results could impair market confidence	Continued R&D, post-market surveillance
Supply chain disruptions	Manufacturing delays, increased costs	Diversify suppliers, inventory management

Key Financial Metrics

Metric	2022	2023-2025 Average	2026-2028 Forecast
Revenue ($ billion)	3.2	4.5 – 6.7	8.0 – 12.0
Operating Margin (%)	35–40	40–45	45–50
R&D Spend as % of Revenue	10–12	9–11	8–10
EBITDA ($ billion)	1.2–1.6	2.0 – 4.0	4.0 – 6.0

---

How Do Empagliflozin and Metformin Compare to Competitors?

Parameter	Empagliflozin	Dapagliflozin	Canagliflozin
Brand Name	Jardiance	Farxiga	Invokana
FDA Approval Year	2014	2014	2013
Cardiovascular Benefits	Yes (EMPA-REG OUTCOME)	Yes (DECLARE-TIMI 58)	Yes (CREDENCE trial)
Market Penetration	Highest among SGLT2 inhibitors	Strong, but less cardio-focused	Moderate
Patent Expiry	2022 (US)	2025	2025

Metformin, as a generic drug, dominates the market for first-line therapy but faces low revenue margins, though combination formulations can generate additional revenue streams.

---

Regulatory and Market Entry Barriers

• Stringent regulatory procedures for new formulations or combinations.
• Intellectual property hurdles, especially for combination drugs.
• Market access limitations in low-income regions due to affordability.

---

Strategic Investment Considerations

• Market Expansion: Target emerging markets with increasing T2DM prevalence.
• Combination Products: Focus on fixed-dose combinations with metformin for improved adherence.
• Post-Patent Strategies: Invest in biosimilars and generics post-expiry to sustain revenue.
• Pipeline Diversification: Support R&D for novel SGLT2 inhibitors and cardio-renal indications.
• Partnerships & Alliances: Collaborations with healthcare providers and payers to boost access.

---

FAQs

1. What factors most influence the profitability of empagliflozin in the next five years?

Market penetration in emerging regions, loss of patent protection, inclusion in treatment guidelines, and expansion into cardiovascular and renal indications will significantly influence profitability. Cost management and pipeline diversification will be critical to sustain margins.

2. How do regulatory changes impact investments in empagliflozin?

Regulatory authorities may impose stricter criteria for approval of new formulations or label extensions, especially for biosimilars or combination drugs. Pricing regulations and reimbursement policies also impact revenue potential.

3. What is the outlook for biosimilar and generic versions of empagliflozin?

Biosimilars could enter the market post-patent expiry (2022 US expiry), leading to significant price competition. Strategic planning should include R&D to develop or acquire biosimilar assets to mitigate revenue erosion.

4. Which geographic markets offer the highest growth opportunities for empagliflozin?

Emerging markets in Asia-Pacific, Latin America, and Africa exhibit high growth potential due to increasing diabetes prevalence, improving healthcare infrastructure, and rising affluence. Regulatory and reimbursement frameworks are evolving rapidly in these regions.

5. How does combination therapy with metformin influence market dynamics?

Fixed-dose combinations improve compliance, expand prescribing patterns, and can command premium pricing. This synergy enhances market share and creates barriers for competitors.

---

Key Takeaways

• The global diabetes drug market is projected to reach ~$150 billion by 2028, with empagliflozin capturing a significant, growing share due to proven cardio-renal benefits.
• Market growth hinges on clinical evidence, regulatory support, and expanding access in emerging markets.
• Patent expiries and biosimilar development pose competitive risks, but pipeline diversification and combination therapies offer strategic growth avenues.
• Financial forecasts suggest sustained revenue growth with healthy profit margins, provided companies adapt to patent cliff and pricing pressures.
• Investment success depends on early adoption in guidelines, strategic partnerships, and proactive pipeline management.

---

References

[1] Fortune Business Insights, "Diabetes Drugs Market Size & Share," 2022.

[2] EvaluatePharma, "Global Revenue and Market Share of SGLT2 Inhibitors," 2022.

[3] Zinman et al., "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes," NEJM, 2015.

---

Note: All projections are estimates based on current data and market trends; actual outcomes may vary due to regulatory, technological, or geopolitical factors.